Sophiris Bio (NASDAQ:SPHS) Cut to Sell at ValuEngine

ValuEngine cut shares of Sophiris Bio (NASDAQ:SPHS) from a hold rating to a sell rating in a report published on Tuesday, ValuEngine reports.

A number of other brokerages have also recently commented on SPHS. Piper Jaffray Companies dropped their price objective on shares of Sophiris Bio to $5.00 and set an overweight rating on the stock in a research note on Wednesday, March 13th. Maxim Group reaffirmed a hold rating on shares of Castle Brands in a research note on Wednesday, June 19th. Finally, HC Wainwright decreased their target price on Sophiris Bio from $10.00 to $3.50 and set a buy rating on the stock in a research report on Thursday, March 14th.

Shares of NASDAQ:SPHS opened at $0.96 on Tuesday. Sophiris Bio has a twelve month low of $0.71 and a twelve month high of $3.49. The stock has a 50 day simple moving average of $0.82. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 2.93. The firm has a market cap of $33.54 million, a P/E ratio of -1.84 and a beta of 2.80.

Sophiris Bio (NASDAQ:SPHS) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.02. On average, research analysts anticipate that Sophiris Bio will post -0.36 EPS for the current year.

A hedge fund recently raised its stake in Sophiris Bio stock. Geode Capital Management LLC raised its position in Sophiris Bio Inc (NASDAQ:SPHS) by 14.9% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 243,523 shares of the biopharmaceutical company’s stock after purchasing an additional 31,579 shares during the period. Geode Capital Management LLC owned 0.81% of Sophiris Bio worth $202,000 at the end of the most recent quarter. Institutional investors own 8.27% of the company’s stock.

Sophiris Bio Company Profile

Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.

Recommended Story: How are capital gains distributions different for tax-deferred account?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with's FREE daily email newsletter.